Business
Immunome to Present at the Stifel 2023 Healthcare Conference
SEATTLE & EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class
About this update from Immunome, Inc.
[{"type":"text","content":" SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.\n\n\nInterested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.\n\n\nAbout Immunome, Inc.\n\n\nImmunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.\n\n\nFor more information, visit www.immunome.com or follow us on Twitter and LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20231110745339/en/\n\nInvestor Contact\nCorleen Roche\nChief Financial Officer\[email protected]\n\n\nMedia Contact\nAndrew W. Mielach\nLifeSci Communications\[email protected]\n\n\nSource: Immunome, Inc.","length":4045,"tagName":"div"}]